Evaluation of the Safety and Tolerance of Immunotherapy With Autologous, Ex-Vivo Expanded, HIV-Specific Cytotoxic T-Cells in HIV-Infected Patients With CD4+ Counts Between 100-400/mm3
PHASE1CompletedINTERVENTIONAL
Enrollment
15
Participants
Timeline
Start Date
Not specified
Study Completion Date
June 30, 2002
Conditions
HIV Infections
Interventions
DRUG
Lymphocytes, Activated
Trial Locations (1)
02111
New England Med Ctr / Tufts Univ, Boston
All Listed Sponsors
lead
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
NCT00000756 - Evaluation of the Safety and Tolerance of Immunotherapy With Autologous, Ex-Vivo Expanded, HIV-Specific Cytotoxic T-Cells in HIV-Infected Patients With CD4+ Counts Between 100-400/mm3 | Biotech Hunter | Biotech Hunter